Clinical Trial Update: Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating gemcitabine and nab-paclitaxel with Hedgehog inhibitor LDE-225 as neoadjuvant therapy for pancreatic ductal adenocarcinoma; study ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• LDE-225 (LDE-225)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-06-25